According to the agreement, both the organizations will conduct proof-of-concept, safety and functional studies for immunomodulatory approach to treat type 1 diabetes.
Sanofi global diabetes senior vice president Pierre Chancel said, "By working together to translate academic knowledge into know-how about a potential new drug target, we hope to discover revolutionary new options for patients living with type 1 diabetes worldwide."
Sanofi has an option to exclusively license intellectual property emerging from the collaboration. Financial details of the deal have been kept confidential.
BWH research senior vice president Barbara Bierer said, "This strategic collaboration brings further recognition to the outstanding research of the renowned Brigham scientist Vijay Kuchroo, D.V.M., Ph.D. and his colleagues including, Drs. Terry Strom and Maria Koulmanda from Beth Israel Deaconess Medical Center (BIDMC), and the importance of the translation of fundamental discoveries into routine clinical practice."